EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions

Gracia Maria Vargas iD, Mohammad Saad Farooq, Giorgos C Karakousis

Cancers · 29.07.2024 · 16 (15) · 2690

DOI: 10.3390/cancers16152690 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.07.2024. Verfasst von Gracia Maria Vargas und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrine and Oncologic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, …. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma is the fifth most common cancer in the United States and accounts for the majority of all skin cancer-related deaths, making it the most lethal cutaneous malignancy. Systemic adjuvant therapy for stage IIB-IV melanoma is now approved for patients who have undergone surgical resection, given the appreciable risk of recurrence and mortality in this patient population. Despite the lower stage, high-risk stage II melanoma (stage IIB/IIC) can often exhibit an even more aggressive course when compared to stage IIIA/IIIB disease, thus justifying consideration of adjuvant therapy in these patients. In this review, we highlight the current standard of practice for the treatment of stage IIB/C melanoma, with a focus on adjuvant therapies supported by published landmark clinical trials, including anti-PD-1 therapy. Notably, adjuvant therapies approved thus far in this patient population have demonstrated an improvement in recurrence-free survival, while their impact on overall survival is pending. Finally, this review highlights currently ongoing trials and future directions for research and treatment possibilities for high-risk clinical stage II melanoma.

Schlagwörter

Stichwörter der Autor:innen

PD-1 inhibitorsadjuvant therapyhigh-risk stage II melanomaimmune checkpoint inhibitorsnivolumabpembrolizumabrandomized clinical trialsrecurrence-free survivalsentinel lymph node biopsytargeted therapy

Autor:innen und Institutionen

  • Division of Endocrine and Oncologic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

ORCID-Profile: Gracia Maria Vargas

Förderung

  • NCI NIH HHS

Zitieren

APA

Vargas, G. M., Farooq, M. S., & Karakousis, G. C. (2024). Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions. Cancers, 16(15), 2690. https://doi.org/10.3390/cancers16152690

Vancouver

Vargas GM, Farooq MS, Karakousis GC. Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions. Cancers. 2024;16(15):2690. doi:10.3390/cancers16152690

BibTeX
@article{Vargas2024,
  author = {Vargas, Gracia Maria and Farooq, Mohammad Saad and Karakousis, Giorgos C},
  title = {Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {15},
  pages = {2690},
  doi = {10.3390/cancers16152690}
}
Kostenlos starten →